Detail page

Knowledge Web

Person

Bertram Bengsch (1982-)

Arzt

Name	Bertram Bengsch
Time	1982- (Date of birth and death)
Place	Singen (Hohentwiel) (Geburtsort) Deutschland
Gender	männlich
Academic degree	Dr. (an der Fakultät für Biologie der Universität Freiburg (Breisgau)) (2013)
Profession	Arzt (characteristic profession)
Variant	Bertram Rüdiger Bengsch
Further information	Diss. Universität Freiburg, Medizinische Fakultät
Record type	Person
GND-Identifier	136789242
Record ID	136789242
Involved in show all Prevention of relapse of juvenile myelomonocytic leukemia (JMML) by inhibition of immune checkpoint CD47 Hepatocellular Carcinoma – from Immunobiology to Immunotherapy Expansion of a distinct cytotoxic CD4 TFH-cell cluster in lymph nodes of patients with complicated Common Variable Immunodeficiency Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations Deep sequencing of circulating tumour DNA as a biomarker of clinical outcome to transarterial chemoembolisation in hepatocellular carcinoma Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of esophageal adenocarcinoma A proteotranscriptomic approach to dissect the molecular landscape of human retinoblastoma Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity Characteristic immune cell interactions in livers of children with acute hepatitis revealed by spatial single-cell analysis identify a possible postacute sequel of COVID-19 Deep sequencing of circulating tumour DNA as a biomarker of clinical outcome to transarterial chemoembolisation in hepatocellular carcinoma Differentiation-associated ISG expression of NK cells in chronic viral infection Dynamic evolution of TCF3-PBX1 leukemias at the single‐cell level under chemotherapy pressure Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of esophageal adenocarcinoma Impact of ALDH1A1 expression in intrahepatic cholangiocellular carcinoma Impaired SARS-CoV-2-specific CD8+ T cells after infection or vaccination but robust hybrid T cell immunity in patients with multiple myeloma In-Depth Molecular Characterization of Neovascular Membranes Suggests a Role for Hyalocyte-to-Myofibroblast Transdifferentiation in Proliferative Diabetic Retinopathy Limited vaccine-induced CD8+ T cell immunity in HIV-infected immunological nonresponders Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinoma Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1+CD8+ T cells Attenuated effector T cells are linked to control of chronic HBV infection High throughput spatial immune mapping reveals an innate immune scar in post-COVID-19 brains Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome Prostaglandin E2 controls the metabolic adaptation of T cells to the intestinal microenvironment AI-assisted high-throughput tissue microarray workflow Attenuated effector T cells are linked to control of chronic HBV infection Efficacy, safety and differential outcomes of immune‐chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: a multicenter real world cohort High throughput spatial immune mapping reveals an innate immune scar in post-COVID-19 brains Impaired SARS-CoV-2-specific CD8+ T cells after infection or vaccination but robust hybrid t cell immunity in patients with multiple myeloma MCAM is a prognostic biomarker in patients with liver cirrhosis and HCC Prostaglandin E2 controls the metabolic adaptation of T cells to the intestinal microenvironment Safety and preliminary efficacy of pembrolizumab following transarterial chemoembolization for hepatocellular carcinoma: the PETAL phase Ib study Senolytic therapy alleviates physiological human brain aging and COVID-19 neuropathology Harnessing CD3 diversity to optimize CAR T cells Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients Capillary electrophoresis mass spectrometry identifies new isomers of inositol pyrophosphates in mammalian tissues Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: a global, observational study Enolase represents a metabolic checkpoint controlling the differential exhaustion programmes of hepatitis virus-specific CD8+T cells Enolase represents a metabolic checkpoint controlling the differential exhaustion programmes of hepatitis virus-specific CD8<sup>+</sup>T cells Friend or foe – Tc17 cell generation and current evidence for their importance in human disease Harnessing CD3 diversity to optimize CAR T cells Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma Morphologic and molecular analysis of liver injury after SARS-CoV-2 vaccination reveals distinct characteristics P1000: Juvenile myelomonocytic leukemia (JMML) inhibits t cell proliferation via the ectonucleotidase cd39 and the purinergic network Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC : : an international observational study Senolytic therapy alleviates physiological human brain aging and COVID-19 neuropathology T cells in the heterogeneous tumour immune microenvironment of hepatocellular carcinoma: Implications for immune checkpoint inhibitor therapy Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunity COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation High-dimensional profiling reveals Tc17 cell enrichment in active Crohn’s disease and identifies a potentially targetable signature Distinct CD8 T Cell Populations with Differential Exhaustion Profiles Associate with Secondary Complications in Common Variable Immunodeficiency Neue Therapieoptionen beim HCC* COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation Distinct CD8 T cell populations with differential exhaustion profiles associate with secondary complications in common variable immunodeficiency High-dimensional profiling reveals Tc17 cell enrichment in active Crohn’s disease and identifies a potentially targetable signature Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunity P328: Dynamic evolution of TCF3-PBX1 leukemias at the single-cell level under chemotherapy pressure

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Bertram Bengsch (1982-)

Prevention of relapse of juvenile myelomonocytic leukemia (JMML) by inhibition of immune checkpoint CD47

Hepatocellular Carcinoma – from Immunobiology to Immunotherapy

Expansion of a distinct cytotoxic CD4 TFH-cell cluster in lymph nodes of patients with complicated Common Variable Immunodeficiency

Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations

Deep sequencing of circulating tumour DNA as a biomarker of clinical outcome to transarterial chemoembolisation in hepatocellular carcinoma

Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of esophageal adenocarcinoma

A proteotranscriptomic approach to dissect the molecular landscape of human retinoblastoma

Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity

Characteristic immune cell interactions in livers of children with acute hepatitis revealed by spatial single-cell analysis identify a possible postacute sequel of COVID-19

Deep sequencing of circulating tumour DNA as a biomarker of clinical outcome to transarterial chemoembolisation in hepatocellular carcinoma

Differentiation-associated ISG expression of NK cells in chronic viral infection

Dynamic evolution of TCF3-PBX1 leukemias at the single‐cell level under chemotherapy pressure

Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of esophageal adenocarcinoma

Impact of ALDH1A1 expression in intrahepatic cholangiocellular carcinoma

Impaired SARS-CoV-2-specific CD8+ T cells after infection or vaccination but robust hybrid T cell immunity in patients with multiple myeloma

In-Depth Molecular Characterization of Neovascular Membranes Suggests a Role for Hyalocyte-to-Myofibroblast Transdifferentiation in Proliferative Diabetic Retinopathy

Limited vaccine-induced CD8+ T cell immunity in HIV-infected immunological nonresponders

Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab

Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinoma

Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1+CD8+ T cells

Attenuated effector T cells are linked to control of chronic HBV infection

High throughput spatial immune mapping reveals an innate immune scar in post-COVID-19 brains

Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome

Prostaglandin E2 controls the metabolic adaptation of T cells to the intestinal microenvironment

AI-assisted high-throughput tissue microarray workflow

Attenuated effector T cells are linked to control of chronic HBV infection

Efficacy, safety and differential outcomes of immune‐chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: a multicenter real world cohort

High throughput spatial immune mapping reveals an innate immune scar in post-COVID-19 brains

Impaired SARS-CoV-2-specific CD8+ T cells after infection or vaccination but robust hybrid t cell immunity in patients with multiple myeloma

MCAM is a prognostic biomarker in patients with liver cirrhosis and HCC

Prostaglandin E2 controls the metabolic adaptation of T cells to the intestinal microenvironment

Safety and preliminary efficacy of pembrolizumab following transarterial chemoembolization for hepatocellular carcinoma: the PETAL phase Ib study

Senolytic therapy alleviates physiological human brain aging and COVID-19 neuropathology

Harnessing CD3 diversity to optimize CAR T cells

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma

Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients

Capillary electrophoresis mass spectrometry identifies new isomers of inositol pyrophosphates in mammalian tissues

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: a global, observational study

Enolase represents a metabolic checkpoint controlling the differential exhaustion programmes of hepatitis virus-specific CD8+T cells

Enolase represents a metabolic checkpoint controlling the differential exhaustion programmes of hepatitis virus-specific CD8<sup>+</sup>T cells

Friend or foe – Tc17 cell generation and current evidence for their importance in human disease

Harnessing CD3 diversity to optimize CAR T cells

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

Morphologic and molecular analysis of liver injury after SARS-CoV-2 vaccination reveals distinct characteristics

P1000: Juvenile myelomonocytic leukemia (JMML) inhibits t cell proliferation via the ectonucleotidase cd39 and the purinergic network

Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC : : an international observational study

Senolytic therapy alleviates physiological human brain aging and COVID-19 neuropathology

T cells in the heterogeneous tumour immune microenvironment of hepatocellular carcinoma: Implications for immune checkpoint inhibitor therapy

Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunity

COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation

High-dimensional profiling reveals Tc17 cell enrichment in active Crohn’s disease and identifies a potentially targetable signature

Distinct CD8 T Cell Populations with Differential Exhaustion Profiles Associate with Secondary Complications in Common Variable Immunodeficiency

Neue Therapieoptionen beim HCC*

COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation

Distinct CD8 T cell populations with differential exhaustion profiles associate with secondary complications in common variable immunodeficiency

High-dimensional profiling reveals Tc17 cell enrichment in active Crohn’s disease and identifies a potentially targetable signature

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunity

P328: Dynamic evolution of TCF3-PBX1 leukemias at the single-cell level under chemotherapy pressure